These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28906028)

  • 41. Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients.
    Manlhiot C; Pollock-Barziv SM; Holmes C; Weitzman S; Allen U; Clarizia NA; Ngan BY; McCrindle BW; Dipchand AI
    J Heart Lung Transplant; 2010 Jun; 29(6):648-57. PubMed ID: 20304682
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Complete response to post-transplant lymphoproliferative disorder by surgical resection and rituximab after living-donor liver re-transplantation for recurrent primary sclerosing cholangitis.
    Haruki K; Shiba H; Shimada J; Okui N; Iida T; Yanaga K
    Clin J Gastroenterol; 2017 Feb; 10(1):47-51. PubMed ID: 27796825
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
    Zimmermann H; Babel N; Dierickx D; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Bachy E; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S; Trappe RU
    Transplantation; 2018 Nov; 102(11):1914-1923. PubMed ID: 29757894
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Early diagnosis and comprehensive treatments of post-transplantation lymphoproliferative disorder after pediatric liver transplantation].
    Deng Z; Jiang L; Zhou T; Shen C; Chen Q; Xia Q
    Zhonghua Er Ke Za Zhi; 2014 Aug; 52(8):579-82. PubMed ID: 25224233
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Steroid-free immunosuppression after renal transplantation-long-term experience from a single centre.
    El-Faramawi M; Rohr N; Jespersen B
    Nephrol Dial Transplant; 2006 Jul; 21(7):1966-73. PubMed ID: 16574678
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy.
    Al-Akash SI; Al Makadma AS; Al Omari MG
    Pediatr Transplant; 2005 Apr; 9(2):249-53. PubMed ID: 15787802
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Abdominal involvement in pediatric heart and lung transplant recipients with posttransplant lymphoproliferative disease increases the risk of mortality.
    Tai CC; Curtis JL; Szmuszkovicz JR; Horn MV; Ford HR; Woo MS; Wang KS
    J Pediatr Surg; 2008 Dec; 43(12):2174-7. PubMed ID: 19040929
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
    Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Steroid-free maintenance immunosuppression using alemtuzumab in pediatric kidney transplantation: Long-term longitudinal follow-up.
    Jain A; Daoud D; Kees-Folts D; Freeman MA; Butt F; Abendroth CS; Shike H; Kadry Z
    Pediatr Transplant; 2022 Mar; 26(2):e14173. PubMed ID: 34687570
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
    Gross TG; Bucuvalas JC; Park JR; Greiner TC; Hinrich SH; Kaufman SS; Langnas AN; McDonald RA; Ryckman FC; Shaw BW; Sudan DL; Lynch JC
    J Clin Oncol; 2005 Sep; 23(27):6481-8. PubMed ID: 16170157
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Critical evaluation of rituximab rescue in 27 patients with different types of kidney disease.
    Ganzemueller J; Hartmann B; Keller F; Stracke S
    Minerva Urol Nefrol; 2011 Dec; 63(4):263-72. PubMed ID: 21996981
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.
    Evens AM; David KA; Helenowski I; Nelson B; Kaufman D; Kircher SM; Gimelfarb A; Hattersley E; Mauro LA; Jovanovic B; Chadburn A; Stiff P; Winter JN; Mehta J; Van Besien K; Gregory S; Gordon LI; Shammo JM; Smith SE; Smith SM
    J Clin Oncol; 2010 Feb; 28(6):1038-46. PubMed ID: 20085936
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.
    Miyagi S; Sekiguchi S; Kawagishi N; Akamatsu Y; Satoh K; Takeda I; Fukushima D; Kobayashi Y; Tokodai K; Fujimori K; Satomi S
    Transplant Proc; 2011 Nov; 43(9):3299-301. PubMed ID: 22099782
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Post-transplant lymphoproliferative disease in heart and lung transplantation: Defining risk and prognostic factors.
    Kumarasinghe G; Lavee O; Parker A; Nivison-Smith I; Milliken S; Dodds A; Joseph J; Fay K; Ma DD; Malouf M; Plit M; Havryk A; Keogh AM; Hayward CS; Kotlyar E; Jabbour A; Glanville AR; Macdonald PS; Moore JJ
    J Heart Lung Transplant; 2015 Nov; 34(11):1406-14. PubMed ID: 26279197
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Posttransplant Lymphoproliferative Disorder in Adults Receiving Kidney Transplantation in British Columbia: A Retrospective Cohort Analysis.
    Ready E; Chernushkin K; Partovi N; Hussaini T; Luo C; Johnston O; Shapiro RJ
    Can J Kidney Health Dis; 2018; 5():2054358118760831. PubMed ID: 29636980
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment.
    Garcia VD; Bonamigo Filho JL; Neumann J; Fogliatto L; Geiger AM; Garcia CD; Barros V; Keitel E; Bittar AE; Ferrera des Santos A; Roithmann S
    Transpl Int; 2003 Mar; 16(3):202-6. PubMed ID: 12664217
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients.
    Milpied N; Vasseur B; Parquet N; Garnier JL; Antoine C; Quartier P; Carret AS; Bouscary D; Faye A; Bourbigot B; Reguerre Y; Stoppa AM; Bourquard P; Hurault de Ligny B; Dubief F; Mathieu-Boue A; Leblond V
    Ann Oncol; 2000; 11 Suppl 1():113-6. PubMed ID: 10707791
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sirolimus for pediatric liver transplant recipients with post-transplant lymphoproliferative disease and hepatoblastoma.
    Jiménez-Rivera C; Avitzur Y; Fecteau AH; Jones N; Grant D; Ng VL
    Pediatr Transplant; 2004 Jun; 8(3):243-8. PubMed ID: 15176961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.